title: Development of oxytocin- and vasopressin-network in the supraoptic and paraventricular nuclei of fetal sheep.
abstract: The hypothalamic supraoptic and paraventricular nuclei consist of oxytocin and arginine vasopressin synthesizing neurons that send projections to the neurohypophysis. A growing body of evidence in adult animals and young animals at near term confirmed the structure and function in the vasopressinergic and oxytocinergic network. However, whether those distinctive neural networks are formed before near term is largely unknown. This study determined the special patterns in location and distribution of oxytocin- and vasopressin-neurons in the paraventricular and supraoptic nuclei from preterm to term in the ovine fetuses. The results showed that oxytocin- and vasopressin-neurons were present in both nuclei at the three gestational time periods (preterm, near term, and term). In the paraventricular nuclei, vasopressin-cells concentrated mainly in the core of the middle magnocellular paraventricular nuclei, and oxytocin-cells were scattered surrounding the core. In the supraoptic nuclei, vasopressin-cells mostly located in the ventral part, and oxytocin-cells in the dorsal part. The data demonstrated that the special distributed patterns of vasopressin- and oxytocin-neuron network have formed in those two nuclei at least from preterm. Intracerebroventricular injection of angiotensin II significantly increased fetal plasma oxytocin and vasopressin levels at preterm, which was associated with an increase of oxytocin- and vasopressin-neuron activity marked with c-fos expression. The data provided new evidence for the structural and functional development of the oxytocin- and vasopressin-network before birth.
authors.affiliation: Beijing Sport University, Beijing China.
authors.forename: L
authors.initials: L
authors.lastname: Shi
authors.forename: Y
authors.initials: Y
authors.lastname: Fan
authors.forename: Z
authors.initials: Z
authors.lastname: Xu
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D005260:Female; D005865:Gestational Age; D007276:Injections, Intraventricular; D009415:Nerve Net / Q000196:embryology / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D010121:Oxytocin / Q000097:blood / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D011247:Pregnancy; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D012756:Sheep; D013495:Supraoptic Nucleus / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D013997:Time Factors
chemical_list: D016760:Proto-Oncogene Proteins c-fos; D000804:Angiotensin II; D001127:Arginine Vasopressin; D010121:Oxytocin